The global single nucleotide polymorphism (SNP) genotyping market size reached US$ 9.8 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 37.9 Billion by 2032, exhibiting a growth rate (CAGR) of 16.2% during 2023-2032. The growing genotype research and development activities, rising demand for personalized medicine and novel drug delivery systems, and increasing demand for genetic analysis in animal and plant feedstock represent some of the key factors driving the market.
Single nucleotide polymorphism (SNP) genotyping is a technique designed to identify and analyze genetic variations among individuals by examining specific locations within their deoxyribonucleic acid (DNA) sequence. It involves determining the specific nucleotide present at a particular SNP site in the DNA of an individual. It relies on advanced molecular biology techniques, such as polymerase chain reaction (PCR) and DNA sequencing, wherein PCR amplifies the DNA segment containing the SNP, and then the nucleotide at the SNP site is determined either by directly sequencing the amplified DNA or using other methods like microarrays or allele-specific PCR. It aids in understanding population genetics, migration patterns, and evolutionary history. It plays a crucial role in determining response to medications, predicting disease susceptibility, and tailoring treatments to specific genetic profiles. SNP genotyping is used by researchers to study the genetic basis of complex diseases, identify genetic risk factors, and develop enhanced diagnostic tools.
Single nucleotide polymorphism (SNP) genotyping is a technique designed to identify and analyze genetic variations among individuals by examining specific locations within their deoxyribonucleic acid (DNA) sequence. It involves determining the specific nucleotide present at a particular SNP site in the DNA of an individual. It relies on advanced molecular biology techniques, such as polymerase chain reaction (PCR) and DNA sequencing, wherein PCR amplifies the DNA segment containing the SNP, and then the nucleotide at the SNP site is determined either by directly sequencing the amplified DNA or using other methods like microarrays or allele-specific PCR. It aids in understanding population genetics, migration patterns, and evolutionary history. It plays a crucial role in determining response to medications, predicting disease susceptibility, and tailoring treatments to specific genetic profiles. SNP genotyping is used by researchers to study the genetic basis of complex diseases, identify genetic risk factors, and develop enhanced diagnostic tools.
Single Nucleotide Polymorphism (SNP) Genotyping Market Trends:
At present, the increasing demand for SNP genotyping on account of the rising genotype research and development activities and bioinformatics in the development of diagnostic tools or effective therapeutics for various diseases represents one of the crucial factors supporting the growth of the market. In addition, the growing utilization of SNP genotyping in the etiology of various human diseases, such as cancer, cardiovascular, Alzheimer's, and asthma, is offering a favorable market outlook. Besides this, there is a rise in the demand for SNP genotyping to establish genetic relationships, resolve paternity disputes, and assist in criminal investigations around the world. This, along with the thriving medical industry, is propelling the growth of the market. Moreover, the increasing demand for pharmacogenomics due to the rising pipeline for personalized medicine and novel drug delivery systems is strengthening the growth of the market. Apart from this, numerous technologies of SNP genotyping in the life science field, such as agricultural biotechnology, diagnostic research, pharmaceuticals, pharmacogenomics, and animal and livestock breeding, are contributing to the growth of the market. In line with this, the growing prevalence of diabetes, cardiovascular diseases, and cancer across the globe is positively influencing the market. Furthermore, the rising demand for genetic analysis in animal and plant feedstock is bolstering the growth of the market.Key Market Segmentation:
The publisher provides an analysis of the key trends in each segment of the global single nucleotide polymorphism (SNP) genotyping market, along with forecasts at the global, regional, and country levels from 2024-2032. The report has categorized the market based on technology and application.Technology Insights:
- TaqMan SNP Genotyping
- Massarray SNP Genotyping
- SNP GeneChip Arrays
- Others
Application Insights:
- Animal Genetics
- Plant Improvement
- Diagnostic Research
- Pharmaceuticals and Pharmacogenomics
- Agricultural Biotechnology
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global single nucleotide polymorphism (SNP) genotyping market. Detailed profiles of all major companies have been provided. Some of the companies covered include Agilent Technologies Inc., Eurofins Genomics (Eurofins Scientific SE), Illumina Inc., Integrated DNA Technologies, Inc. (Danaher Corporation), LGC Limited, PREMIER Biosoft, Promega Corporation, QIAGEN N.V, Roche Holding AG, Thermo Fisher Scientific Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.Key Questions Answered in This Report:
- How has the global single nucleotide polymorphism (SNP) genotyping market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global single nucleotide polymorphism (SNP) genotyping market?
- What is the impact of each driver, restraint, and opportunity on the global single nucleotide polymorphism (SNP) genotyping market?
- What are the key regional markets?
- Which countries represent the most attractive single nucleotide polymorphism (SNP) genotyping market?
- What is the breakup of the market based on the technology?
- Which is the most attractive technology in the single nucleotide polymorphism (SNP) genotyping market?
- What is the breakup of the market based on the application?
- Which is the most attractive application in the single nucleotide polymorphism (SNP) genotyping market?
- What is the competitive structure of the global single nucleotide polymorphism (SNP) genotyping market?
- Who are the key players/companies in the global single nucleotide polymorphism (SNP) genotyping market?
Table of Contents
1 Preface3 Executive Summary10 Value Chain Analysis12 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Single Nucleotide Polymorphism (SNP) Genotyping Market
6 Market Breakup by Technology
7 Market Breakup by Application
8 Market Breakup by Region
9 Drivers, Restraints, and Opportunities
11 Porters Five Forces Analysis
13 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Agilent Technologies Inc.
- Eurofins Genomics (Eurofins Scientific SE)
- Illumina Inc.
- Integrated DNA Technologies Inc. (Danaher Corporation)
- LGC Limited
- PREMIER Biosoft
- Promega Corporation
- QIAGEN N.V
- Roche Holding AG
- Thermo Fisher Scientific Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 149 |
| Published | March 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 9.8 Billion |
| Forecasted Market Value ( USD | $ 37.9 Billion |
| Compound Annual Growth Rate | 16.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
